From their April trial update announcement regarding Reach2HD...

From their April trial update announcement regarding Reach2HD says results anticipated in October:

Huntington Disease Trial Update - the "Reach2HD" trial

The Reach2HD trial is a 6 month trial in 109 patients with early to mid-stage Huntington disease. The trial is being conducted across sites in the USA and Australia. The following provides an update on the trial:

Last Patient recruited December 2012;
Last Patient to be Dosed June 2013;
Results anticipated October 2013;
97% of patients have completed 12 weeks of dosing (equal to previous longest exposure of PBT2);
32% of patients have completed 6 months of dosing;
Data Safety Monitoring Board met on 28 March, 2013, with the recommendation to continue the trial without any changes to the original protocol.
Only one drug is marketed for Huntington disease and that is only for the relief of the severe motor or chorea symptoms. There are no approved treatments for the significant cognitive and behavioural components of the disease, which typically manifest before motor problems.

Alzheimer's disease Trial Update - the "IMAGINE" trial

In an earlier 12 week trial PBT2 both significantly changed amyloid levels in spinal fluid and improved the cognition of patients with Alzheimer's disease.1,2 The IMAGINE trial, with 12 months of treatment, aims to establish PBT2 as a safe and effective treatment for Alzheimer's disease. The following provides an update on the trial:

Last Patient recruited November 2012;
Last Patient to be Dosed November 2013;
Trial will be completed in December 2013;
7% of patients have completed 12 months of dosing, over 4 times longer than the previous longest exposure to PBT2;
50% of patients have reached 26 weeks of dosing;
Data Safety Monitoring Board met on 27 March, 2013, with the recommendation to continue the trial without any changes to the original protocol.